ALEC:NSD-Alector Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.52

Change

+0.03 (+0.40)%

Market Cap

USD 0.64B

Volume

0.33M

Avg Analyst Target

USD 16.00 (+112.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALEC Stock Forecast & Price:
Based on the Alector Inc stock forecasts from 3 analysts, the average analyst target price for Alector Inc is USD 16.00 over the next 12 months. Alector Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alector Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Alector Inc’s stock price was USD 7.52. Alector Inc’s stock price has changed by -4.20% over the past week, -21.01% over the past month and -61.14% over the last year.

About Alector Inc (ALEC:NSD)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.58% 41% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.58% 41% F 25% F
Trailing 12 Months  
Capital Gain -63.58% 48% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.58% 48% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.12% 62% D- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.12% 62% D- 39% F
Risk Return Profile  
Volatility (Standard Deviation) 46.50% 43% F 27% F
Risk Adjusted Return -2.41% 62% D- 46% F
Market Capitalization 0.64B 78% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.92 38% F 62% D-
Price/Book Ratio 2.54 40% F 33% F
Price / Cash Flow Ratio 2.15 7% F 37% F
EV/EBITDA 0.55 19% F 43% F
Management Effectiveness  
Return on Equity -46.35% 62% D- 31% F
Return on Invested Capital -13.15% 83% B 39% F
Return on Assets -10.21% 89% B+ 36% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.99 22% F 13% F
Short Percent 8.15% 24% F 19% F
Beta 0.98 60% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.